We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Non-Invasive Melanoma Test Ushers in New Era in Skin Cancer Detection

By LabMedica International staff writers
Posted on 25 Jan 2023
Print article
Image: Smart Stickers are changing the way melanoma is detected (Photo courtesy of DermTech)
Image: Smart Stickers are changing the way melanoma is detected (Photo courtesy of DermTech)

Skin cancer overall is the most common form of cancer with melanoma being the third most common and also the most aggressive form of skin cancer. Now, an innovative test painlessly collect cells from the skin and applies precision genomics to diagnose melanoma accurately and at the earliest curable stage.

The DermTech Melanoma Test from DermTech (La Jolla, CA, USA) is a non-invasive genomic test that enables early detection of melanoma by identifying the presence of genomic markers found in melanoma – often much earlier than the current biopsy pathway. The Smart Sticker gently lifts skin cells containing genomic material from the surface of the skin while the adhesive on the sticker stores and preserves the skin cells so that it can be sent to DermTech’s Gene Lab for examination.

Using a proprietary precision genomic test, DermTech’s genomic analysis looks for melanoma at the gene level, 10,000 times closer than even a microscope. The test detects LINC00518 and PRAME using RT-PCR which makes billions of copies of these genes. An additional test can also be conducted to identify the presence of TERT gene driver mutations using a DNA sequencing technique. Positive results for LINC00518, PRAME, or TERT correlate with the presence of melanoma. If the genomic markers found in melanoma are present, this will typically result in a biopsy of the spot. If the biomarkers are not detected (meaning negative results), there could be a greater than 99% probability that the mole being tested is not melanoma.

The Smart Sticker uses a specially formulated adhesive to gently lift skin cells from the surface of the skin, but it is not strong enough to cause pain, bleeding or damage to the site. The DermTech Melanoma Test is not a replacement for a biopsy. If the genomic markers exist, then the doctor can use this information to choose the best path forward for the patient’s treatment. The DermTech Melanoma Test is rather a step before a biopsy that can see genomic markers linked to melanoma far earlier than the traditional biopsy pathway can.

Related Links:

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
POCT Fluorescent Immunoassay Analyzer
Myoglobin Emergency Marker

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.